Download PDF
Endoscopy 2006; 38(2): 162-169
DOI: 10.1055/s-2005-921184
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Surveillance in Barrett’s Oesophagus: Will a Strategy Focused on a High-Risk Group Reduce Mortality from Oesophageal Adenocarcinoma?

R.  Quera1, 2 , K.  O’Sullivan3 , E.  M.  M.  Quigley1
  • 1Alimentary Pharmabiotic Centre, Department of Medicine, National University of Ireland, Cork, Ireland
  • 2Department of Gastroenterology, Clinical Hospital of the University of Chile, Santiago, Chile
  • 3Department of Statistics, National University of Ireland, Cork, Ireland
Further Information

Publication History

Submitted 24 April 2005

Accepted after revision 9 September 2005

Publication Date:
14 February 2006 (online)

Also available at
    Permissions and Reprints

Background and Study Aims: The incidence of oesophageal adenocarcinoma has increased significantly in recent years. While surveillance of people with Barrett’s oesophagus, its usual precursor, has been advocated in order to detect dysplasia and early cancer in those considered to be at greatest risk, the impact of such a strategy on survival from oesophageal adenocarcinoma is unclear. This study aimed to determine the effect of surveillance on mortality from oesophageal adenocarcinoma in a group of patients considered to be at high risk of developing Barrett’s oesophagus and adenocarcinoma.
Patients and Methods: After performing a Medline search of the literature published between 1985 and 2004 for studies on gastro-oesophageal reflux disease, Barrett’s oesophagus and adenocarcinoma, we examined the impact of surveillance on mortality from oesophageal adenocarcinoma in a hypothetical sample of 100 high-risk patients (men aged over 50 with Barrett’s oesophagus but without high-grade dysplasia at entry).
Results: Four patients in this high-risk group developed adenocarcinoma during surveillance, with survival rates of 78.9 % (95 %CI 64.9 % - 88.5 %) at 2 years and 78.6 % (95 %CI 62.8 % - 89.2 %) at 5 years. Meanwhile, between 515 and 2060 patients with Barrett’s oesophagus were not detected or surveyed by this strategy and between 16 and 61 of these developed adenocarcinoma, with much lower survival rates of 37.1 % (95 %CI 25.4 % - 50.3 %) at 2 years and 16.7 % (95 %CI 9 % - 28.3 %) at 5 years. Although surveillance in the high-risk group resulted in the long-term survival of three patients who would not otherwise have survived, this gain was dramatically offset by the 13 to 51 patients, excluded from surveillance by this strategy, who died from oesophageal adenocarcinoma.
Conclusions: A surveillance programme based on current concepts of risk cannot have an impact on mortality from oesophageal adenocarcinoma. To be effective, it will be necessary for surveillance programmes to utilise more precise methods for the identification of those who are most at risk of progression to adenocarcinoma.

References

  • 1 Williamson W A, Ellis F H Jr, Gibb S P. et al . Barrett’s esophagus. Prevalence and incidence of adenocarcinoma.  Arch Intern Med. 1991;  151 2212-2216
    CrossrefPubMedGoogle Scholar
  • 2 Spechler S J. Clinical practice: Barrett’s esophagus.  N Engl J Med. 2002;  346 836-842
    CrossrefPubMedGoogle Scholar
  • 3 Jankowski J A, Wright N A, Meltzer S J. et al . Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.  Am J Pathol. 1999;  154 965-973
    CrossrefPubMedGoogle Scholar
  • 4 Jankowski J A, Harrison R F, Perry I. et al . Barrett’s metaplasia.  Lancet. 2000;  356 2079-2085
    CrossrefPubMedGoogle Scholar
  • 5 Reid B J. Barrett’s esophagus and esophageal adenocarcinoma.  Gastroenterol Clin North Am. 1991;  20 817-834
    PubMedGoogle Scholar
  • 6 Theisen J, Nigro J J, DeMeester T R. et al . Chronology of the Barrett’s metaplasia-dysplasia-carcinoma sequence.  Dis Esophagus. 2004;  17 67-70
    CrossrefPubMedGoogle Scholar
  • 7 Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?.  Gastroenterology. 2000;  119 333-338
    CrossrefPubMedGoogle Scholar
  • 8 Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.  Cancer. 1998;  83 2049-2053
    CrossrefPubMedGoogle Scholar
  • 9 Sampliner R E. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Practice Parameters Committee of the American College of Gastroenterology.  Am J Gastroenterol. 2002;  97 1888-1895
    CrossrefPubMedGoogle Scholar
  • 10 Dulai G S, Guha S, Kahn K L. et al . Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review.  Gastroenterology. 2002;  122 26-33
    CrossrefPubMedGoogle Scholar
  • 11 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.  N Engl J Med. 1999;  340 825-831
    CrossrefPubMedGoogle Scholar
  • 12 Fleiss J L. Statistical methods for rates and proportions. New York; John Wiley & Sons 1981
    Google Scholar
  • 13 Hirota W K, Loughney T M, Lazas D J. et al . Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.  Gastroenterology. 1999;  116 277-285
    CrossrefPubMedGoogle Scholar
  • 14 Csendes A, Smok G, Burdiles P. et al . Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux.  Dis Esophagus. 2003;  16 24-28
    CrossrefPubMedGoogle Scholar
  • 15 Cameron A J, Kamath P S, Carpenter H A. Barrett’s esophagus: the prevalence of short and long segments in reflux patients.  Gastroenterology. 1995;  108 A65
    PubMedGoogle Scholar
  • 16 Cameron A J, Kamath P S, Carpenter H A. Prevalence of esophagus and intestinal metaplasia at the esophagogastric junction.  Gastroenterology. 1997;  112 A82
    PubMedGoogle Scholar
  • 17 Chalasani N, Wo J M, Hunter J G, Waring J P. Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction.  Dig Dis Sci. 1997;  42 603-607
    CrossrefPubMedGoogle Scholar
  • 18 Rex D X, Cummings O W, Shaw M. et al . Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn.  Gastroenterology. 2003;  125 1670-1677
    CrossrefPubMedGoogle Scholar
  • 19 Schnell T, Sontag S, Warner J. et al . Endoscopic screening for Barrett’s esophagus (BE), esophageal adenocarcinoma (AdCa) and other mucosal changes in ambulatory subjects with symptomatic gastroesophageal reflux (GER).  Gastroenterology. 1985;  88 1576
    PubMedGoogle Scholar
  • 20 Winters C Jr, Spurlin T J, Chobanian S J. et al . Barrett’s esophagus: a prevalent, occult complication of gastroesophageal disease.  Gastroenterology. 1987;  92 118-124
    CrossrefPubMedGoogle Scholar
  • 21 Mann N S, Tsai M F, Nair P K. Barrett’s esophagus in patients with symptomatic reflux esophagitis.  Am J Gastroenterol. 1989;  84 1494-1496
    PubMedGoogle Scholar
  • 22 Abo S R, Stevens P D, Abedi M. et al . Prevalence of short-segment Barrett’s epithelium in patients with gastroesophageal reflux disease.  Gastroenterology. 1995;  108 A43
    PubMedGoogle Scholar
  • 23 Corder A P, Jones R H, Sadler G H. et al . Heartburn, oesophagitis and Barrett’s oesophagus in self-medicating patients in general practice.  Br J Clin Pract. 1996;  50 245-248
    PubMedGoogle Scholar
  • 24 Robinson M, Earnest D, Rodriguez-Stanley S. et al . Heartburn requiring frequent antacid use may indicate significant illness.  Arch Intern Med. 1998;  158 2373-2376
    CrossrefPubMedGoogle Scholar
  • 25 Dietz J, Meurer L, Maffazzoni D R. et al . Intestinal metaplasia in the distal esophagus and correlation with symptoms of gastroesophageal reflux disease.  Dis Esophagus. 2003;  16 29-32
    CrossrefPubMedGoogle Scholar
  • 26 Morales T G, Sampliner R E, Bhattacharyya A. Intestinal metaplasia of the gastric cardia.  Am J Gastroenterol. 1997;  92 414-418
    PubMedGoogle Scholar
  • 27 Conio M, Blanchi S, Lapertosa G. et al . Long-term endoscopic surveillance of patients with Barrett’s esophagus - incidence of dysplasia and adenocarcinoma: a prospective study.  Am J Gastroenterol. 2003;  98 1931-1939
    CrossrefPubMedGoogle Scholar
  • 28 O’Connor J B, Falk G W, Ritcher J E. The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s Esophagus Registry.  Am J Gastroenterol. 1999;  94 2037-2042
    PubMedGoogle Scholar
  • 29 Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s esophagus.  Gut. 1991;  32 1441-1446
    PubMedGoogle Scholar
  • 30 Weston A P, Badr A S, Hassanein R S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett’s multifocal high-grade dysplasia or adenocarcinoma.  Am J Gastroenterol. 1999;  94 3413-3419
    CrossrefPubMedGoogle Scholar
  • 31 Cameron A J, Lomboy C T. Barrett’s esophagus: age, prevalence, and extent of columnar epithelium.  Gastroenterology. 1992;  103 1241-1245
    CrossrefPubMedGoogle Scholar
  • 32 Macdonald C E, Wicks A C, Playford R J. Final results from 10 years cohort of patients undergoing surveillance for Barrett’s esophagus: observational study.  BMJ. 2000;  321 1252-1255
    CrossrefPubMedGoogle Scholar
  • 33 Murray L, Watson P, Johnston B. et al . Risk of adenocarcinoma in Barrett’s esophagus: population based study.  BMJ. 2003;  327 534-535
    CrossrefPubMedGoogle Scholar
  • 34 Gopal D V, Lieberman D A, Magaret N. et al . Risk factors for dysplasia in patients with Barrett’s esophagus (BE): results from a multicenter consortium.  Dig Dis Sci. 2003;  48 1537-1541
    CrossrefPubMedGoogle Scholar
  • 35 Weston A P, Banerjee S K, Sharma P. et al . p53 Protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: inmunohistochemical marker predictive of progression.  Am J Gastroenterol. 2001;  96 1355-1362
    CrossrefPubMedGoogle Scholar
  • 36 Benipal P, Garewal H S, Sampliner R E. et al . Short segment Barrett’s esophagus: relationship of age with extent of intestinal metaplasia.  Am J Gastroenterol. 2001;  96 3084-3088
    CrossrefPubMedGoogle Scholar
  • 37 Hameeteman W, Tytgat G NJ, Houthoff H J, van den Tweel J G. Barrett’s esophagus: development of dysplasia and adenocarcinoma.  Gastroenterology. 1989;  96 1249-1256
    PubMedGoogle Scholar
  • 38 Schnell T G, Sontag S J, Chejfec G. et al . Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia.  Gastroenterology. 2001;  120 1607-1619
    CrossrefPubMedGoogle Scholar
  • 39 Lao C D, Simmons M, Syngal S. et al . Dysplasia in Barrett’s esophagus.  Cancer. 2004;  100 1622-1627
    CrossrefPubMedGoogle Scholar
  • 40 Cameron A J, Zinsmeister A R, Ballard D J, Carney J A. Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings.  Gastroenterology. 1990;  99 918-922
    PubMedGoogle Scholar
  • 41 Prach A T, Macdonald T A, Hopwood D A, Johnston D A. Increasing incidence of Barrett’s esophagus: education, enthusiasm, or epidemiology?.  Lancet. 1997;  350 933
    PubMedGoogle Scholar
  • 42 Montgomery E, Goldblum J R, Greenson J K. et al . Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.  Hum Pathol. 2001;  32 379-388
    CrossrefPubMedGoogle Scholar
  • 43 Reid B J, Levine D S, Longton G. et al . Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subset.  Am J Gastroenterol. 2000;  95 1669-1676
    PubMedGoogle Scholar
  • 44 Burdiles P, Csendes A, Smok G. et al . Progression from intestinal metaplasia to adenocarcinoma in Barrett’s esophagus: usefulness of endoscopic surveillance.  Rev Med Chil. 2003;  131 587-596
    PubMedGoogle Scholar
  • 45 Skacel M, Petras R E, Gramlich T L. et al . The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression.  Am J Gastroenterol. 2000;  95 3383-3387
    CrossrefPubMedGoogle Scholar
  • 46 Eckardt V F, Kanzler M D, Bernhard G. Life expectancy and cancer risk in patients with Barrett’s esophagus: a prospective controlled investigation.  Am J Med. 2001;  111 33-37
    CrossrefPubMedGoogle Scholar
  • 47 Katz D, Rothstein R, Schned A. et al . The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett’s esophagus.  Am J Gastroenterol. 1998;  93 536-541
    CrossrefPubMedGoogle Scholar
  • 48 Sharma P, Morales T G, Bhattacharayya A. et al . Dysplasia in short-segment Barrett’s esophagus: a prospective 3-year follow-up.  Am J Gastroenterol. 1997;  92 2012-2016
    PubMedGoogle Scholar
  • 49 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;  92 212-215
    PubMedGoogle Scholar
  • 50 Conio M, Cameron A J, Romero Y. et al . Secular trends in the epidemiology and outcome of Barrett’s oesophagus in Olmsted County, Minnesota.  Gut. 2001;  48 304-309
    CrossrefPubMedGoogle Scholar
  • 51 Wright T A, Gray M R, Morris A I. et al . Cost-effectiveness of detecting Barrett’s cancer.  Gut. 1996;  39 574-579
    CrossrefPubMedGoogle Scholar
  • 52 Robertson C S, Mayberry J F, Nicholson D A. et al . Value of endoscopic surveillance in the detection of neoplastic change in Barrett’s oesophagus.  Br J Surg. 1988;  75 760-763
    PubMedGoogle Scholar
  • 53 Ovaska J, Miettinen M, Kivilaasko E. Adenocarcinoma arising in Barrett’s esophagus.  Dig Dis Sci. 1989;  34 1336-1339
    CrossrefPubMedGoogle Scholar
  • 54 Sampliner R E, Machel C, Fennerty M B. Prospective incidence of cancer in Barrett’s oesophagus.  Gastroenterology. 1991;  100 A153
    PubMedGoogle Scholar
  • 55 Iftikhar S Y, James P D, Steele R J. et al . Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma.  Gut. 1992;  33 1155-1158
    CrossrefPubMedGoogle Scholar
  • 56 Ferraris R, Bonelli L, Conio M. et al . Incidence of Barrett’s adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio della Precancerosi Esopagee (GOSPE).  Eur J Gastroenterol Hepatol. 1997;  9 881-885
    CrossrefPubMedGoogle Scholar
  • 57 Levine D S, Haggitt R C, Blount P T. et al . An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus.  Gastroenterology. 1993;  105 40-50
    CrossrefPubMedGoogle Scholar
  • 58 Peters J H, Clark G W, Ireland A P. et al . Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients.  J Thorac Cardiovasc Surg. 1994;  108 813-821
    PubMedGoogle Scholar
  • 59 Tseng E E, Wu T T, Yeo C J, Heitmiller R F. Barrett’s esophagus with high-grade dysplasia: surgical results and long-term outcome - an update.  J Gastrointest Surg. 2003;  7 164-170
    CrossrefPubMedGoogle Scholar
  • 60 Thomson B N, Cade R J. Oesophagectomy for early adenocarcinoma and dysplasia arising in Barrett’s oesophagus.  ANZ J Surg. 2003;  73 121-124
    CrossrefPubMedGoogle Scholar
  • 61 Reid B J, Weinstein W M, Lewin K J. et al . Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions.  Gastroenterology. 1988;  94 81-90
    PubMedGoogle Scholar
  • 62 Nigro J J, Hagen J A, DeMeester T R. et al . Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy.  Ann Surg. 1999;  230 433-440
    CrossrefPubMedGoogle Scholar
  • 63 Zaninotto G, Parenti A R, Ruol A. et al . Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus.  Br J Surg. 2000;  87 1102-1105
    CrossrefPubMedGoogle Scholar
  • 64 Buttar N S, Wang K K, Sebo T J. et al . Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.  Gastroenterology. 2001;  120 1630-1639
    CrossrefPubMedGoogle Scholar
  • 65 Heitmiller R F, Redmond M, Hamilton S R. Barrett’s esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy.  Ann Surg. 1996;  224 66-71
    CrossrefPubMedGoogle Scholar
  • 66 Pellegrini C A, Pohl D. High-grade dysplasia in Barrett’s esophagus: surveillance or operation?.  J Gastrointest Surg. 2000;  4 131-134
    CrossrefPubMedGoogle Scholar
  • 67 Romagnoli R, Collard J M, Gustschow C. et al . Outcomes of dysplasia arising in Barrett’s esophagus: a dynamic view.  J Am Coll Surg. 2003;  197 365-371
    CrossrefPubMedGoogle Scholar
  • 68 van Sandick J W, van Lanschot J J, Kuiken B W. et al . Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma.  Gut. 1998;  43 216-222
    CrossrefPubMedGoogle Scholar
  • 69 Incarbone R, Bonavina L, Saino G. et al . Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett’s esophagus.  Surg Endosc. 2002;  16 263-266
    CrossrefPubMedGoogle Scholar
  • 70 Headrick J R, Nichols F C IIIrd, Miller D L. et al . High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy.  Ann Thorac Surg. 2002;  73 1697-1702
    Google Scholar
  • 71 Rice T W, Falk G, Achkar E, Petras P E. Surgical management of high-grade dysplasia in Barrett’s esophagus.  Am J Gastroenterol. 1993;  88 1832-1836
    PubMedGoogle Scholar
  • 72 Pera M, Trastek V F, Carpenter H A. et al . Barrett’s esophagus with high-grade dysplasia: an indication for esophagectomy?.  Ann Thorac Surg. 1992;  54 199-204
    CrossrefPubMedGoogle Scholar
  • 73 Edwards M J, Gable D R, Lentsch A B, Richardson J D. The rationale for esophagectomy as the optimal therapy for Barrett’s esophagus with high-grade dysplasia.  Ann Surg. 1996;  223 585-589
    CrossrefPubMedGoogle Scholar
  • 74 Altorki N K, Sunagawa M, Little A G, Skinner D B. High-grade dysplasia in the columnar-lined esophagus.  Am J Surg. 1991;  161 97-99
    CrossrefPubMedGoogle Scholar
  • 75 Menke-Pluymers M B, Schoute N W, Mulder A H. et al . Outcome of surgical treatment of adenocarcinoma in Barrett’s oesophagus.  Gut. 1992;  33 1454-1458
    CrossrefPubMedGoogle Scholar
  • 76 Corley D A, Levin T R, Habel L A. et al . Surveillance and survival in Barrett’s adenocarcinoma: a population-based study.  Gastroenterology. 2002;  122 633-640
    CrossrefPubMedGoogle Scholar
  • 77 Streitz J M Jr, Andrews C W Jr, Ellis F H Jr. Endoscopic surveillance of Barrett’s esophagus: does it help?.  J Thorac Cardiovasc Surg. 1993;  105 383-387
    PubMedGoogle Scholar
  • 78 Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar-lined epithelium (Barrett’s esophagus).  N Eng J Med. 1985;  313 857-859
    CrossrefPubMedGoogle Scholar
  • 79 Van der Veen A H, Dees J, Blankensteijn J D, Blankenstein M. Adenocarcinoma in Barrett’s esophagus: an overrated risk.  Gut. 1989;  30 14-18
    PubMedGoogle Scholar
  • 80 Van der Burgh A, Dees J, Hop W C, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus.  Gut. 1996;  39 5-8
    PubMedGoogle Scholar
  • 81 Spechler S J, Barr H. Review article: screening and surveillance of Barrett’s oesophagus: what is a cost-effective framework?.  Aliment Pharmacol Ther. 2004;  19 (Suppl 1) 49-53
    CrossrefPubMedGoogle Scholar
  • 82 Anderson L A, Murray L J, Murphy S J. et al . Mortality in Barrett’s oesophagus: results from a population based study.  Gut. 2003;  52 1081-1084
    CrossrefPubMedGoogle Scholar
  • 83 Sharma P, McQuaid K, Dent J. et al . A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago workshop.  Gastroenterology. 2004;  127 310-330
    CrossrefPubMedGoogle Scholar
  • 84 Ramnath G, Bampton P. Surveillance for Barrett’s oesophagus: if you do it, do it properly.  Med J Aust. 2004;  180 139-140
    PubMedGoogle Scholar
  • 85 Patti M G, Corvera C U, Glasgow R E, Way L W. A hospital’s annual rate of esophagectomy influences the operative mortality rate.  J Gastrointest Sug. 1998;  2 186-192
    CrossrefPubMedGoogle Scholar
  • 86 Swisher S G, Deford I, Merriman K W. et al . Effects of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer.  J Thorac Cardiovasc Surg. 2000;  19 1126-1132
    PubMedGoogle Scholar
  • 87 Birkemeyer J D, Siewers A E, Finlayson E W. et al . Hospital volume and surgical mortality in the United States.  New Engl J Med. 2002;  346 1128-1137
    CrossrefPubMedGoogle Scholar
  • 88 Streitz J M Jr, Ellis F H Jr, Tilden R L, Erickson R V. Endoscopic surveillance of Barrett’s esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.  Am J Gastroenterol. 1998;  93 911-915
    PubMedGoogle Scholar
  • 89 Provenzale D, Schmitt C, Wong J B. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk.  Am J Gastroenterol. 1999;  94 2043-2053
    CrossrefPubMedGoogle Scholar
  • 90 Sonnenberg A, Soni A, Sampliner R E. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma.  Aliment Pharmacol Ther. 2002;  16 41-50
    CrossrefPubMedGoogle Scholar
  • 91 Shaheen N J, Provenzale D, Sandler R S. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence.  Am J Gastroenterol. 2002;  97 1319-1327
    CrossrefPubMedGoogle Scholar
  • 92 Inadomi J M, Sampliner R, Lagergren J. et al . Screening and surveillance for Barrett’s esophagus in a high-risk group: a cost-utility analysis.  Ann Intern Med. 2003;  138 176-186
    CrossrefPubMedGoogle Scholar
  • 93 Eisen G M, Sandler R S, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus.  Am J Gastroenterol. 1997;  92 27-31
    PubMedGoogle Scholar
  • 94 McManus D T, Olaru A, Meltzer S J. Biomarkers of esophageal adenocarcinoma and Barrett’s esophagus.  Cancer Res. 2004;  64 1561-1569
    CrossrefPubMedGoogle Scholar
  • 95 Faruqi S A, Arantes V, Bhutani M S. Barrett’s esophagus: current and future role of endosonography and optical coherence tomography.  Dis Esophagus. 2004;  17 118-123
    CrossrefPubMedGoogle Scholar

E. M. M. Quigley, M. D.

Alimentary Pharmabiotic Centre · Department of Medicine · Cork University Hospital · Cork · Ireland

Fax: +353-21-490-1289

Email: e.quigley@ucc.ie

      >